Sage Therapeutics

$64.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$4.28 (+7.11%) Today
-$0.46 (-0.71%) As of 7:31 AM EST after-hours

Why Robinhood?

You can buy or sell SAGE and other stocks, options, ETFs, and crypto commission-free!

About SAGE

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. Read More The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.

Employees
637
Headquarters
Cambridge, Massachusetts
Founded
2010
Market Cap
3.12B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
2.86M
High Today
$65.83
Low Today
$61.02
Open Price
$62.86
Volume
5.59M
52 Week High
$193.56
52 Week Low
$56.50

Collections

SAGE News

BenzingaDec 6

Sell-Side Remains Optimistic On Sage Therapeutics Despite Depression Drug Disappointment

Sage Therapeutics Inc (NASDAQ: SAGE) shares fell more than 60% Thursday following a negative readout for its lead asset in major depressive disorder. The Analy
163
ReutersDec 5

Sage shares sink as depression therapy fails much-awaited trial

(Reuters) - Sage Therapeutics Inc said on Thursday its experimental fast-acting drug aimed at treating severe depression failed a closely-watched study, sending
542
MarketWatchDec 5

Sage Therapeutics's stock plunges after depression treatment study fails primary endpoint

Shares of Sage Therapeutics Inc. SAGE, -0.38% plummeted 59% toward a 2-year low to pace all premarket decliners Thursday, after the biopharmaceutical company sa
925

SAGE Earnings

-$3.48
-$2.44
-$1.40
-$0.36
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
Actual
Expected Feb 18, Pre-Market

You May Also Like

Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.
Search
LearnBlogCareersHelpLog InSign Up